Revenues for the quarter were $74.9 million, up from $68.2 million during the first quarter of 2004. Bruker Daltonics, Bruker's mass spectrometry operating business that includes instruments used for proteomics, contributed $42.6 million to total revenues, a 10-percent increase over last year's revenues. $29.8 million of the unit's revenues came from sales of life-science mass spectrometry systems.
Research and development expenses increased to $11 million from $9.9 million during the same quarter last year.
The company's net income fell to $400,000, or $0 per share, from $500,000, or $.01 per share, during the same period a year ago.
As of March 31, Bruker BioSciences had $84.8 million in cash and short-term investments.